Real-world clinical outcomes and rationale for initiating abatacept as a first-line biologic for patients with anticitrullinated protein antibody- and rheumatoid factor-positive rheumatoid arthritis
Journal of Comparative Effectiveness Research · 2024
DOI: 10.57264/cer-2023-0144 ↗Kurz gefasst
Fachartikel in der Zeitschrift Journal of Comparative Effectiveness Research, 2024. Verfasst von Alexandrina Balanean und 12 weiteren Autor:innen. Beteiligte Einrichtung: Cardinal Health, Dublin, OH 43017, USA. Hauptthemen laut MEDLINE: Abatacept, Arthritis, Rheumatoid, Antirheumatic Agents, Rheumatoid Factor. Die Arbeit wurde bisher 4-mal zitiert (Crossref) und nennt 60 Literaturangaben. Der Volltext ist frei in PubMed Central verfügbar.
Abstract (Originalsprache)
Aim
In rheumatoid arthritis (RA), seropositivity for both anticitrullinated protein antibody (ACPA) and rheumatoid factor (RF) is associated with disease severity and therapeutic response. Biologic (b) disease-modifying antirheumatic drugs (DMARDs) such as abatacept are recommended after inadequate response or contraindication to conventional synthetic DMARDs. This retrospective cohort study aimed to describe changes in Clinical Disease Activity Index (CDAI) measures over 12 months among patients with ACPA+ and RF+ RA with an inadequate response to methotrexate treated with abatacept as a first-line bDMARD. Patients & methods: Patient data were abstracted from medical records by treating rheumatologists. Analyses included McNemar tests for paired proportions or paired t -tests to assess longitudinal changes in CDAI scores, and Kaplan–Meier methods for time-to-event outcomes. Serious AEs and rationale for initiating treatment were recorded.
Results
Overall, 296 patients were included. Mean CDAI scores improved (decreased) by 34.0, 61.0 and 74.0% (all p < 0.001) from baseline to 3–6 months, 6–12 months and ≥12 months after abatacept initiation, respectively. Of 279 patients not in CDAI low disease activity (LDA) or remission at baseline, 24.7% of patients achieved it within 6 months, 56.3% within 12 months and 71.0% at any point during follow-up after abatacept initiation. Median time to CDAI LDA/remission was 10.2 months. Serious AEs were reported in 2.4% of patients. Common reasons reported by rheumatologists for initiating abatacept were effectiveness/efficacy (52.7%), safety (31.4%) and patient preference (25.3%).
Conclusion
In this analysis of patients with ACPA+ and RF+ RA treated with abatacept as a first-line bDMARD in a clinical practice setting, clinical outcomes and remission rates were improved at all time points, providing real-world evidence to further support the use of abatacept in this patient population.
Schlagwörter
MeSH-Schlagwörter (MEDLINE)
Stichwörter der Autor:innen
Substanzen
Autor:innen und Institutionen
- Cardinal Health, Dublin, OH 43017, USA.
- Bristol Myers Squibb, Princeton, NJ 08540, USA.
- Arthritis & Osteoporosis Consultants of the Carolinas, Charlotte, NC 28207, USA.
ORCID-Profile: Andrew Klink, Vardhaman Patel, Hanke Zheng, Keith Wittstock, Bruce Feinberg
Zitieren
APA
Balanean, A., Brown-Bickerstaff, C., Klink, A., Patel, V., Zheng, H., N'Dri, L., Wittstock, K., Feinberg, B., Chaballa, M., Khaychuk, V., Kaufman, J., Pathak, P., & Lam, G. (2024). Real-world clinical outcomes and rationale for initiating abatacept as a first-line biologic for patients with anticitrullinated protein antibody- and rheumatoid factor-positive rheumatoid arthritis. Journal of Comparative Effectiveness Research. https://doi.org/10.57264/cer-2023-0144
Vancouver
Balanean A, Brown-Bickerstaff C, Klink A, Patel V, Zheng H, N'Dri L, et al. Real-world clinical outcomes and rationale for initiating abatacept as a first-line biologic for patients with anticitrullinated protein antibody- and rheumatoid factor-positive rheumatoid arthritis. Journal of Comparative Effectiveness Research. 2024. doi:10.57264/cer-2023-0144
BibTeX
@article{Balanean2024,
author = {Balanean, Alexandrina and Brown-Bickerstaff, Cherrishe and Klink, Andrew and Patel, Vardhaman and Zheng, Hanke and N'Dri, Laetitia and Wittstock, Keith and Feinberg, Bruce and Chaballa, Mark and Khaychuk, Vadim and Kaufman, Jill and Pathak, Prathamesh and Lam, Gordon},
title = {Real-world clinical outcomes and rationale for initiating abatacept as a first-line biologic for patients with anticitrullinated protein antibody- and rheumatoid factor-positive rheumatoid arthritis},
journal = {Journal of Comparative Effectiveness Research},
year = {2024},
doi = {10.57264/cer-2023-0144}
}
EUVIMED